PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Hepatology3 citations

Two decades of hepatitis E in solid organ transplantation: A retrospective monocentric analysis

View Full Paper
NKNassim KamarFAFlorence AbravanelOMOlivier Marion

Key Result

Ribavirin serves as the cornerstone treatment for frequent hepatitis E infections in solid organ transplant recipients, where individualized therapy duration improves clinical outcomes.

Key Points

  • This research aims to analyze the incidence and implications of hepatitis E virus (HEV) infection in solid organ transplant (SOT) recipients over two decades.
  • Conducted a retrospective analysis at a single center
  • Examined incidence of HEV in SOT recipients
  • Analyzed treatment regimens, including ribavirin
  • Evaluated screening practices and liver enzyme levels among patients
  • HEV infection is common in SOT patients with a notable rate of chronic infections
  • Ribavirin treatment significantly improves patient outcomes
  • Mandatory screening is essential for patients with elevated liver enzymes to prevent complications

Structured PICO

P
Population
Solid organ transplantation (SOT) recipients with Hepatitis E virus (HEV) infection
I
Intervention
Ribavirin

In solid organ transplant recipients with HEV infection, ribavirin is the cornerstone of treatment and individualized duration improves outcomes.

Abstract

HEV infection is frequent in SOT recipients, with significant risks of chronicity and extrahepatic complications. Ribavirin remains the cornerstone of treatment, and individualized duration improves outcomes. Screening for HEV is mandatory in SOT patients with elevated liver enzymes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kamar et al. (2026) studied this question. Ribavirin serves as the cornerstone treatment for frequent hepatitis E infections in solid organ transplant recipients, where individualized therapy duration improves clinical outcomes.

synapsesocial.com/papers/69d1fcc0a79560c99a0a273ahttps://doi.org/10.1097/hep.0000000000001762
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lower hepatitis E clearance rates in thoracic organ recipients compared to visceral organ recipients: an effect of stronger immunosuppression?2026
  2. 2The high burden of HEV infection in solid organ transplant recipients2025 · 4 citations
  3. 3Hepatitis E Infection and the Question of Screening Organ Donors2024
  4. 4Reduction of immunosuppressants fails to clear hepatitis E virus infection in a heart transplant recipient2026
  5. 5Seroprevalence of hepatitis E virus among solid organ transplant recipients: insights from southern Iran.2025